Saisei Ventures Launches Bridge to Revitalize Japan's Biotech Scene

TOKYO, Japan – February 09, 2026 – Life sciences venture capital firm Saisei Ventures today announced the launch of Bridge-to-Biotech, a venture creation initiative aimed at transforming Japan's vast reservoir of scientific discovery into globally competitive biotechnology companies. The program, launched with support from Japan's Ministry of Health, Labour and Welfare (MHLW), is designed to provide critical, early-stage support to academic scientists and entrepreneurs, addressing a long-standing gap between the lab bench and the global market.

Based in both Tokyo and Cambridge, Massachusetts, Saisei Ventures is positioning this initiative as a vital link in a national effort to invigorate Japan's pharmaceutical innovation landscape. By engaging with founders at the earliest stages of discovery, the program intends to provide the strategic guidance and operational support necessary to build venture-ready enterprises from the ground up.

Addressing a Critical Innovation Gap

For decades, Japan has been a powerhouse of fundamental scientific research, producing world-class discoveries and Nobel laureates. However, the country has historically struggled to translate this academic excellence into commercial success within the biotech sector. A persistent 'valley of death' exists between groundbreaking research and the formation of viable, well-funded startups.

Industry analyses highlight a stark contrast with Western ecosystems. In the United States, for instance, over 50% of FDA-approved drugs in recent years have originated from academic labs or biotech ventures. In Japan, that figure languishes at around 10%. This disparity is rooted in a combination of factors, including a scarcity of early-stage venture capital, a cultural environment in academia that prioritizes publication over commercialization, and a lack of experienced mentors who can guide scientists through the complex process of company building.

Historically, Japan's pharmaceutical giants often focused on developing 'me-too' drugs rather than pioneering novel biotechnologies, further dampening the ecosystem for disruptive innovation. Bridge-to-Biotech is engineered to directly confront these challenges by providing a structured pathway for scientists to develop not just their science, but also a robust commercial vision.

A New Blueprint for Venture Creation

Bridge-to-Biotech is not a traditional accelerator or a simple funding mechanism. Saisei Ventures describes it as a true "venture creation program," offering hands-on support independent of an immediate investment decision. This model allows the firm to engage with promising ideas at their most nascent stage, helping shape their trajectory long before they are ready for a seed funding round.

The program provides founders with a comprehensive toolkit for company formation. This includes guidance on designing crucial proof-of-concept experiments, developing strategic plans for Investigational New Drug (IND) applications, and crafting early-stage corporate strategy. Participants will be paired with a network of experienced mentors from the global biotech and pharmaceutical industries who can help them refine their vision and develop compelling materials to attract investors and partners.

“Japan has extraordinary discovery science, but the support needed to build companies often arrives too late or not at all. With the support of Japan’s Ministry of Health, Labour and Welfare, we created Bridge-to-Biotech to engage founders early and surround them with global experts and development partners from day one,” said Jonathan Yeh, Managing Partner at Saisei Ventures, in the official announcement. “At its core, this program is about supporting the next generation of biotech founders, and helping promising ideas grow into companies that can have global patient impact.”

The Power of Public-Private Partnership

The significance of the Bridge-to-Biotech initiative is amplified by its deep integration with Japan's national strategy. The explicit support from the MHLW is more than a simple endorsement; it connects the program to a wider, well-funded government effort to build a robust pharmaceutical startup ecosystem.

In 2023, Saisei Ventures was one of nine venture capital firms accredited by the Japan Agency for Medical Research and Development (AMED) under its "Strengthening Program for Pharmaceutical Startup Ecosystem." This accreditation provides a powerful financial incentive. Biotech ventures that receive investment from Saisei are eligible to apply for AMED grants that can be up to twice the amount of the capital invested by the firm. This "double match up" funding dramatically de-risks early-stage investment and provides startups with a significant capital runway.

The MHLW has outlined its ambitions in a comprehensive white paper and is planning a new 10-year, multi-billion dollar fund to support drug discovery startups, set to launch in fiscal year 2026. Saisei's selection for the MHLW's "Drug Discovery Ecosystem Development Support Project" in September 2025 further solidifies its role as a key partner in executing this national vision. This public-private alignment provides a stable and supportive foundation for the high-risk, long-term nature of biotech innovation.

An East-West Fusion for Global Ambition

At the heart of this new initiative is Saisei Ventures' unique identity. The firm's name, Saisei, means regrowth or rebirth in Japanese, reflecting its mission to revitalize the country's innovation ecosystem. Its operational presence in both Japan and the U.S. biotech hub of Cambridge, Massachusetts, enables a distinctive "East-West fusion" strategy.

The firm, co-founded by Jonathan Yeh—a scientist and entrepreneur with deep experience in commercializing regenerative medicine—is built to combine Western expertise in venture creation, product development, and global market access with Japan's cutting-edge science. The recent appointments of cell and gene therapy expert Dr. Sven Kili as Partner and pharmaceutical executive James Feliciano as Venture Partner underscore this commitment to embedding global experience directly into Japan's ecosystem.

By leveraging its cross-border network, Saisei aims to build companies that are global from day one. The goal is not just to create successful Japanese companies, but to launch globally competitive players capable of bringing innovative therapies to patients worldwide. The firm's existing portfolio, which includes companies like Kenai Therapeutics developing treatments for neurological diseases, already reflects this ambition.

Ultimately, Bridge-to-Biotech represents a comprehensive, multi-faceted approach to a complex problem. By combining mentorship, strategic guidance, and powerful financial incentives within a cross-cultural framework, Saisei Ventures and its government partners are not just funding companies—they are attempting to cultivate a new, self-sustaining entrepreneurial culture that could finally unlock Japan's immense biotech potential on the world stage.